House QALY Bill Overreach Threatens Medicare Price Negotiation Program, Democrats Warn
Executive Summary
Concern about disrupting the implementation of the negotiation program could presage a tough road for the legislation in the Democrat-controlled Senate.
You may also be interested in...
QALY Bill Clears House But Its Vague Ban Against ‘Similar Measures’ Unlikely To Succeed In Senate
The legislation is a ‘Trojan horse’ designed to undermine the Biden Administration’s policies on cutting drug prices, a leading Democrat claims.
Whiteboarding Ideas From Novartis, Novo To Address India’s Elephants In The Room, ‘On Streets’
Senior VPs from Novartis and Novo Nordisk offered suggestions ranging from protecting IP and fixing the perception of “elephants roaming the streets,” to “fit for purpose” global development plans to improve the research landscape in India, during a recent webinar, which also saw academia weighing in on various issues.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.